Furosemide-Digoxin vs. Polidocanol for Cutaneous Warts

NCT07307131 | Completed Phase 2

• 1 other identifier: intralesional treatment warts
• Study Type: interventional
• Target: 64
• Locations: 1 country
• Sites: 1

Brief Summary

This study compares the effectiveness and safety of two different intralesional treatments for cutaneous warts: a combination of furosemide and digoxin versus polidocanol.

Conditions

Cutaneous Warts; Human Papilloma Virus (HPV)

Keywords

Cutaneous warts, human papillomavirus, intralesional therapy, furosemide, digoxin, polidocanol, sclerotherapy

Outcome Measures

Primary Outcomes (1)

• Complete Clinical Response

  100% clearance of the treated wart at the end of the treatment period.

  Up to 8 weeks

Secondary Outcomes (2)

• Incidence and Severity of Adverse Effects

  Throughout the treatment period (up to 8 weeks)

• Recurrence Rate

  6 months post-treatment

Study Arms (2)

Furosemide and digoxin

EXPERIMENTAL

Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml)

Drug: Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml)

Polidocanol

ACTIVE COMPARATOR

Intralesional Polidocanol 2%

Drug: Intralesional polidocanol 2%

Interventions

Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml) DRUG

Group A (Experimental): Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml)

Furosemide and digoxin

Intralesional polidocanol 2% DRUG

Group B (Active Comparator): Intralesional polidocanol 2%

Polidocanol

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients over 18 years of age with single or multiple cutaneous warts.

You may not qualify if:

• History of allergies to the study medications, known cardiac or renal disease, hypertension, pregnancy or lactation, and any signs of systemic or local infection.

Sponsors & Collaborators

• Benha University: lead

Study Sites (1)

faculty of Medicine

Banhā, Qalyubia Governorate, 13518, Egypt

Location

MeSH Terms

Interventions

Digoxin

Intervention Hierarchy (Ancestors)

Digitalis Glycosides; Cardenolides; Cardiac Glycosides; Cardanolides; Steroids; Fused-Ring Compounds; Polycyclic Compounds; Glycosides; Carbohydrates

Study Officials

• Ghada Shams, MD

  Benha University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Masking Details: Single (Participant)
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal investigator

Study Record Dates

• First Submitted: December 14, 2025
• First Posted: December 29, 2025
• Study Start: September 1, 2024
• Primary Completion: March 1, 2025
• Study Completion: September 30, 2025
• Last Updated: January 2, 2026

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

EG (1)